Scarica l'app Stockscreener
1.99
0.50%
-0.01
Dopo l'orario di chiusura:
2.02
0.03
+1.51%
Precedente Chiudi:
$2.00
Aprire:
$2.01
Volume 24 ore:
2.78M
Relative Volume:
0.71
Capitalizzazione di mercato:
$333.57M
Reddito:
$250.00K
Utile/perdita netta:
$-16.78M
Rapporto P/E:
-1.3402
EPS:
-1.4848
Flusso di cassa netto:
$-10.85M
1 W Prestazione:
-4.33%
1M Prestazione:
+5.85%
6M Prestazione:
-3.86%
1 anno Prestazione:
+154.93%
Intervallo 1D:
$1.90
$2.01
Intervallo di 1 settimana:
$1.90
$2.175
Portata 52W:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Nome
Palisade Bio Inc
Settore
Industria
Telefono
(858) 704-4900
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.99 | 333.57M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-26 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-25 | Iniziato | Stifel | Buy |
| 2026-01-09 | Iniziato | B. Riley Securities | Buy |
| 2025-12-29 | Iniziato | Piper Sandler | Overweight |
Palisade Bio Inc Borsa (PALI) Ultime notizie
MSN Money - MSN
Palisade Bio (PALI) price target decreased by 12.09% to 10.20 - MSN
Major share increase and equity plan votes ahead for Palisade Bio (NASDAQ: PALI) - Stock Titan
Palisade Bio Participates in Virtual Investor "What This Means" Segment - 富途牛牛
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN
PALI Should I Buy - Intellectia AI
PALI Palisade Bio posts narrower than expected Q4 2025 loss, shares gain more than four percent.Secondary Offering - Cổng thông tin điện tử tỉnh Lào Cai
Analysts Offer Predictions for Palisade Bio Q1 Earnings - MarketBeat
Brokers Issue Forecasts for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (NASDAQ: PALI) asks shareholders to lift authorized shares to 450M - Stock Titan
Palisade Bio Develops Crohn’s Disease Treatment Following Positive Study - HarianBasis.co
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Insider Monkey
Palisade Bio to present ulcerative colitis data at DDW conference By Investing.com - Investing.com India
Palisade Bio to present ulcerative colitis data at DDW conference - Investing.com
Palisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative Colitis - Quiver Quantitative
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 - GlobeNewswire
5 Best Biotech Stocks Under $10 to Buy - Insider Monkey
Piper Sandler reiterates Overweight rating on Palisade Bio stock By Investing.com - Investing.com South Africa
Piper Sandler reiterates Overweight rating on Palisade Bio stock - Investing.com
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy - MarketBeat
Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI) - MarketBeat
Palisade Bio CEO, CMO to give virtual Needham presentation April 16 - Stock Titan
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - The Manila Times
Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN
Is Palisade Bio (PALI) Stock a future winner | Price at $1.94, Up 1.31%Trending Social Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Earnings Miss: Can Palisade Bio Inc expand its profit margins2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Palisade Bio partners with Iterative Health to advance PALI-2108 - TipRanks
Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - Investing.com Australia
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
Palisade Bio, Inc. (PALI) stock price, news, quote and history - Yahoo Finance UK
Clear Street Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail
Clear Street reiterates Palisade Bio stock rating on trial data By Investing.com - Investing.com South Africa
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - moomoo.com
Palisade Bio Inc Azioni (PALI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):